Short answer
Arcus Biosciences, Inc. (RCUS) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Financial results cover the six months ended June 30, 2026.
Arcus Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Financial results cover the six months ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains the detailed results
- Filing date August 5, 2026 signals a scheduled midyear financial update
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 revenue $41M versus $160M, reflecting the absence of 2025’s $143M etrumadenant catch-up revenue
- Net loss $91M, or $0.72 per share, versus break-even in Q2 2025
- Cash $775M versus $1.01B at December 31, 2025, with funding projected through at least H2 2028
- Casdatifan strategy expanded through BMS, Summit and AVEO collaborations across first- and late-line ccRCC
- Key 2026 catalysts include ARC-20 efficacy, PFS and overall-survival readouts plus PEAK-1 enrollment completion by year-end
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcus Biosciences, Inc. 8-K filings
Get the next RCUS 8-K as it lands
Follow RCUS for push alerts, or ask the research agent what this filing means.